Acute Myeloid Leukemia
This type of cancer: Acute Myeloid Leukemia, can be Discussed in this Thread.
People suffering because of Acute myeloid leukemia may like to share how they cope to help others around the world who may be searching for answers.
New clue to fighting acute myeloid leukemia found
A new clue has been found that may help fight acute myeloid leukemia (AML), the most common form of cancer of the blood and bone marrow, and an aggressive type of cancer. The findings open a new door to treating the disease more effectively. Ref. Source 5i.
93 percent of advanced leukemia patients in remission after immunotherapy
Twenty-seven of 29 patients with an advanced type of leukemia that had proved resistant to multiple other forms of therapy went into remission after their T cells (Disease-fighting immune cells) were genetically engineered to fight their cancers. This study is the first CAR T-cell trial to infuse patients with an even mixture of two types of T cells (Helper and killer cells, which work together to kill cancer). Ref. Source 5k.
FDA approved midostaurin (RYDAPT, Novartis Pharmaceuticals Corp.) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive (FLT3+), as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. April 28, 2017 More Information: Source 9l.
Potential seen for tailoring treatment for acute myeloid leukemia. Rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia. Research on the differing drug response patterns of leukemia stem cells and blasts may show why some attempts to treat are not successful and why some patients relapse. Source 5a.
New therapy for aggressive blood cancer discovered. Acute myeloid leukemia (AML) is the most common form of acute leukemia. It is characterized by an increase of malignant myeloid progenitor cells at the expense of mature blood cells. Only twenty-five percent of all AML patients survive five years beyond the initial diagnosis. Therefore there is an urgent need to deepen the knowledge about this form of blood cancer and to develop new therapeutic approaches. Source 4v.
Bone marrow cancer: Potential drug targets. New research finds that patients with ASXL1-mutant chronic myelomonocytic leukemia -- an uncommon type of cancer of the bone marrow -- have distinctive epigenetic changes that can activate harmful genes and cause the cancer to grow faster. The ASXL1 genetic mutation also can transform the disease into the more aggressive acute myeloid leukemia. Source 9b.